In February 2025, the National Medical Products Administration (NMPA) approved Innogens ultra-long-acting GLP-1 injection for type 2 diabetes, signaling growing government and regulatory support for GLP-1 innovation and boosting industry confidence
Common side effects of Wegovy include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, upset stomach, heartburn, bloating, gas, belching, dizziness, low blood sugar (specifically in people with type 2 diabetes), and runny nose or sore throat
One study author noted, "Understanding the potential side effects of these treatment modalities, though rare, may help individuals and their care teams weigh each treatment's risks and benefits to develop a personalized regimen" [4]
Alcohol addiction similarly dysregulates these dopamine pathways, creating a plausible mechanistic overlap